Pilot Study to Evaluate Intrahepatic and Peripheral Responses to Small Interfering RNA, Imdusiran (AB-729), Among People With Chronic Hepatitis B
Latest Information Update: 01 Aug 2024
At a glance
- Drugs Imdusiran (Primary)
- Indications Hepatitis B
- Focus Pharmacokinetics
- Acronyms i-LIVER
Most Recent Events
- 29 Jul 2024 Status changed from not yet recruiting to recruiting.
- 28 May 2024 Planned initiation date changed from 1 May 2024 to 1 Jul 2024.
- 02 Apr 2024 Planned End Date changed from 1 Jul 2026 to 1 Dec 2026.